Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.45 |
| ▸ | MEN1 | O00255 | 9/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.45 |
| ▸ | HTT | P42858 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | THRB | P10828 | 4/20 | 0.45 |
| ▸ | RECQL | P46063 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1156819 | 1.00 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA | |
| Iodide SCHEMBL31073928 | 1.00 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA | |
| Iodide SCHEMBL23668383 | 1.00 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA | |
| Iodide SCHEMBL1156818 | 1.00 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL3131736 | 0.99 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL22489411 | 0.99 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL13928996 | 0.99 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL766931 | 0.99 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL7604087 | 0.99 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA | |
| Hydrochloric Acid SCHEMBL3020867 | 0.98 | MAPT (0.45) | MAPTMEN1KMT2AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023004364-A2 | SELF-ASSEMBLING NANOMATERIAL FOR THE DETECTION, IMAGING, OR TREATMENT OF CANCER | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-01-26 | — | — | WO | claimed |
| EP-4736737-A1 | MEDICAL CONTROL DEVICE AND MEDICAL OBSERVATION SYSTEM | Sony Olympus Medical Solutions Inc. (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736734-A1 | MEDICAL OBSERVATION SYSTEM, FILTER, AND OPTICAL VIEWING TUBE | Sony Olympus Medical Solutions Inc. (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736736-A1 | MEDICAL CONTROL DEVICE AND MEDICAL OBSERVATION SYSTEM | Sony Olympus Medical Solutions Inc. (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-4691339-A1 | IMAGE GENERATION DEVICE, MEDICAL OBSERVATION SYSTEM, AND IMAGE GENERATION METHOD | Sony Olympus Medical Solutions Inc. (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4678087-A1 | MEDICAL OBSERVATION SYSTEM AND MEDICAL OBSERVATION METHOD | Sony Olympus Medical Solutions Inc. (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20250360218-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-11-27 | — | — | US | disclosed |
| US-20250295295-A1 | MEDICAL OBSERVATION SYSTEM | SONY OLYMPUS MEDICAL SOLUTIONS INC. (JP) | 2025-09-25 | — | — | US | disclosed |
| US-20250288265-A1 | SYSTEMS AND METHODS FOR PERSISTENT URETER VISUALIZATION | STRYKER CORPORATION (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250274666-A1 | MEDICAL CONTROL DEVICE AND MEDICAL OBSERVATION SYSTEM | SONY OLYMPUS MEDICAL SOLUTIONS INC. (JP) | 2025-08-28 | — | — | US | disclosed |
| WO-2023067599-A1 | SYSTEM FOR DETECTING AND/OR ASSESING A SUBDURAL HEMATOMA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-04-27 | — | — | WO | disclosed |
| US-20230086472-A1 | HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF | CSL LIMITED (AU) | 2023-03-23 | — | — | US | disclosed |
| CN-115685676-A | Photosensitive transfer material, light-shielding material, LED array, and electronic device | 富士胶片株式会社 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023004364-A2 | SELF-ASSEMBLING NANOMATERIAL FOR THE DETECTION, IMAGING, OR TREATMENT OF CANCER | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220389080-A1 | RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING | BRACCO SUISSE SA (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-3965057-B1 | METHODS AND APPARATUS FOR DISPLAYING ENHANCED IMAGING DATA ON A CLINICAL IMAGE | INTUITIVE SURGICAL OPERATIONS (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115006529-A | Pickering emulsion drug-loading system with stable protein particles and loaded with photo-thermal agent and chemotherapeutic drug together, and preparation method and application thereof | 华中科技大学 | 2022-09-06 | — | — | CN | disclosed |
| US-11370826-B2 | Recombinant chimeric protein for selectins targeting | BRACCO SUISSE SA (CH) | 2022-06-28 | — | — | US | disclosed |
| EP-3997710-A1 | SYSTEMS AND METHODS FOR PERSISTENT URETER VISUALIZATION | Stryker Corporation (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3965057-A1 | METHODS AND APPARATUS FOR DISPLAYING ENHANCED IMAGING DATA ON A CLINICAL IMAGE | Intuitive Surgical Operations, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360218-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | TSPO, TFAM, MCU | MAPT 2686/4885MEN1 2245/4885KMT2A 3004/4885 |
| US-20220389080-A1 | RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING | SELPLG, SELL, SELE | MAPT 3142/4885MEN1 4580/4885KMT2A 4524/4885 |
| US-11370826-B2 | Recombinant chimeric protein for selectins targeting | SELPLG, SELL, SELE | MAPT 3142/4885MEN1 4580/4885KMT2A 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.